The U.S. Food and Drug Administration (FDA) has appointed Dr. Richard Pazdur as the new Director of the Center for Drug Evaluation and Research (CDER), following the abrupt resignation of former director George Tidmarsh. The transition marks a major leadership shift for the agency’s largest center, which oversees the regulation of prescription drugs, generics, and therapeutic biologics.
A New Chapter at CDER
Dr. Pazdur, a 26-year veteran of the FDA and founding Director of the Oncology Center of Excellence (OCE), will now lead CDER as the agency navigates a period of rapid regulatory reform and internal restructuring. Known for championing accelerated pathways and modernized review processes, Pazdur is widely regarded as a forward-thinking figure in drug regulation.
FDA Commissioner Marty Makary praised the appointment, calling Pazdur “a true regulatory innovator” with the experience needed to advance the agency’s modernization agenda.
Pazdur reportedly declined the role when first approached, according to The Pink Sheet, but accepted shortly after Tidmarsh’s departure.
Background on Tidmarsh’s Resignation
Tidmarsh stepped down after a September LinkedIn post in which he criticized the use of surrogate endpoints in drug development and referenced a product from Aurinia Pharmaceuticals, a company chaired by a former business associate. The post triggered a 20% drop in Aurinia’s stock value and raised concerns about impartiality.
Following a complaint from healthcare investor Kevin Tang, Tidmarsh was placed on administrative leave and later resigned. Aurinia subsequently announced its intention to pursue legal action.
Leadership Amid Agency Turbulence
Pazdur assumes the CDER directorship during a challenging period for the FDA. Earlier this year, federal workforce reduction initiatives resulted in significant staffing cuts, and the agency has seen the departure of several long-time leaders.
Despite the turbulence, Pazdur expressed optimism, stating that he is honored to lead CDER “at a time when the FDA is achieving long-sought regulatory reforms.” His extensive background—including more than 800 publications and leadership roles at the University of Texas MD Anderson Cancer Center—positions him to influence the future of drug development and approval in the U.S.
A Strategic Moment for Drug Regulation
CDER plays a critical role in ensuring the safety, effectiveness, and quality of medications used by millions of Americans. As the center faces increasing demands—ranging from AI-supported drug development to global supply chain pressures—Pazdur’s leadership may help stabilize the agency and advance its modernization efforts.
FDA Commissioner Makary has emphasized a shift toward greater collaboration and transparency across centers, breaking from the historically siloed “fiefdom culture.” Pazdur’s appointment signals continued commitment to this vision.
At EMMA International, we understand how leadership transitions and evolving regulatory priorities can impact the life-sciences sector. Our team supports organizations through the rapidly changing FDA landscape by offering expertise in:
- Regulatory strategy and submission support
- Quality system development and modernization
- Risk-based decision-making frameworks
- Compliance with CDER and CBER expectations
- Audit readiness and remediation
Whether navigating changing review expectations or preparing for FDA interactions, EMMA International helps ensure your regulatory strategy stays aligned, agile, and compliant.
For more information on how EMMA International can assist, visit www.emmainternational.com or contact us at (248) 987-4497 or info@emmainternational.com.
Reference:
Al-Faruque, F. (2025, November 11). Pazdur takes helm at CDER after Tidmarsh departure. Regulatory Affairs Professionals Society.
U.S. Food and Drug Administration. (2025). Public statements and leadership announcements.
